PD173074

Name: PD173074
Brand: Selleck Chemicals
SKU: S1264
Rating: 5 (83 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1264

83 publications

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Selleck's PD173074 has been cited by 83 publications

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )
Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )

Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )

Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )
J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )

Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )
Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

Targets

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1581	NEfvTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEGyNlUh\|ryP	Ml7LV2FPT0WU
KG-1	NYjPXpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37R[WlEPTB;MD6wOVEzQSEQvF2=	NGPSblVUSU6JRWK=
MFM-223	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlP1TWM2OD1yLkKxOVc3KM7:TR?=	NH3BPJFUSU6JRWK=
EoL-1-cell	NV\VbFBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwM{K5PFQh\|ryP	NUXx[nJ4W0GQR1XS
ECC10	M{\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILsUFVKSzVyPUCuN\|M5QThizszN	NVGySo12W0GQR1XS
H-EMC-SS	NH3vS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUO0SG9UUUN3ME2wMlM1PzF3IN88US=>	NH;0WW9USU6JRWK=
AN3-CA	M3vIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwNECxN\|Mh\|ryP	MWPTRW5ITVJ?
HuO-3N1	NYD3UlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjEZ5B1UUN3ME2wMlU1PjV\|IN88US=>	MVvTRW5ITVJ?
RT-112	NF2wcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK1WploUUN3ME2wMlU1PzBzIN88US=>	NIfhZ5RUSU6JRWK=
NEC8	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDRTWM2OD1yLkW2Nlg6KM7:TR?=	NFvlcVRUSU6JRWK=
D-263MG	NWrQU3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3WTWM2OD1yLkexNVU6KM7:TR?=	MXLTRW5ITVJ?
SW962	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoC3TWM2OD1yLke4PVg5KM7:TR?=	NHK3W3RUSU6JRWK=
BV-173	M{DSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nTVWlEPTB;MD64OFYzOyEQvF2=	NFr6d29USU6JRWK=
MFE-280	NHWxUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[zdVB7UUN3ME2wMlg2QDd{IN88US=>	MoK1V2FPT0WU
HuH-7	NF76ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zQOGlEPTB;MT6yOFQ3PCEQvF2=	MV3TRW5ITVJ?
RS4-11	NUP3XIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFwM{O4PFYh\|ryP	MmTVV2FPT0WU
DMS-114	M{LGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j0UmlEPTB;MT6zOlc{PyEQvF2=	NFTLO25USU6JRWK=
MSTO-211H	NULQfHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPCTWM2OD1zLkS3N\|c5KM7:TR?=	NIfFTHJUSU6JRWK=
DU-145	NY[zWHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLjTWM2OD1zLkW4NlE4KM7:TR?=	NIjMenJUSU6JRWK=
A172	M2jtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn1TWM2OD1zLkewN\|U2KM7:TR?=	MVfTRW5ITVJ?
SBC-1	NGnJfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJwMEm0JO69VQ>?	M2fyWHNCVkeHUh?=
H9	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TMS2lEPTB;Mj6xOFMxPiEQvF2=	NGfrWFdUSU6JRWK=
NCI-SNU-1	NV3iVHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfvW5QxUUN3ME2yMlE5Ozl2IN88US=>	M1nZXnNCVkeHUh?=
NCI-H720	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;ZfmlEPTB;Mj6yNVI5OyEQvF2=	MoDXV2FPT0WU
HCC2218	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\KTWM2OD1{LkO3PVM6KM7:TR?=	M4n0OXNCVkeHUh?=
G-401	M2Xs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\NRZRKSzVyPUKuOFcyQDlizszN	MVXTRW5ITVJ?
MPP-89	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPZTZRKSzVyPUKuOFg{PjRizszN	MoHlV2FPT0WU
697	M3PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DsXWlEPTB;Mj62OVM{OSEQvF2=	NYjBPYZpW0GQR1XS
KARPAS-45	NFfxS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3STWM2OD1{LkewO\|Q4KM7:TR?=	NEHtSoFUSU6JRWK=
MG-63	NHW5eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJwOUSyOlIh\|ryP	NV71TlR2W0GQR1XS
NTERA-S-cl-D1	NFjtcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TW[GlEPTB;Mz6wN\|Q4OiEQvF2=	M1PBO3NCVkeHUh?=
G-402	NXTEXIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO4TWM2OD1\|LkGyO\|I4KM7:TR?=	M3m1bnNCVkeHUh?=
NKM-1	M4D1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nHSGlEPTB;Mz6xN\|U3PCEQvF2=	MmnyV2FPT0WU
RH-18	NVzIS\|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e5RmlEPTB;Mz6xPVU6QCEQvF2=	M3;Nd3NCVkeHUh?=
NCI-H1092	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTNwMUm2PUDPxE1?	MlnVV2FPT0WU
RPMI-8226	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLYSYdDUUN3ME2zMlI{PDR5IN88US=>	M1m0ZnNCVkeHUh?=
GAMG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTNwNE[1O\|Yh\|ryP	NYrNVJZFW0GQR1XS
HH	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTNwNEe2O\|Yh\|ryP	NUi1RY1DW0GQR1XS
RO82-W-1	NFHJfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTNwNEm4OVUh\|ryP	NECwe4JUSU6JRWK=
CCRF-CEM	M1\hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkP1TWM2OD1\|LkWwOFg5KM7:TR?=	M1PDeHNCVkeHUh?=
NBsusSR	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PvemlEPTB;Mz62N\|k3QSEQvF2=	MV3TRW5ITVJ?
CHL-1	NX7QXGdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTNwNkW3PVkh\|ryP	M4POS3NCVkeHUh?=
LK-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLPTWM2OD1\|Lk[3NVM{KM7:TR?=	MkXrV2FPT0WU
Hs-578-T	NI[zT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXyeI1TUUN3ME2zMlY4QDd\|IN88US=>	NEfQO3NUSU6JRWK=
CTB-1	NYrxZ3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfyfWRQUUN3ME2zMlgxODVzIN88US=>	MmHwV2FPT0WU
ES5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTNwOEO2N\|ch\|ryP	NIXLTHBUSU6JRWK=
A204	NWXJRXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTNwOUKwO\|Uh\|ryP	NYnNU4NZW0GQR1XS
SW780	NH:2N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIW0RXlKSzVyPUOuPVIzPDVizszN	M3fZbHNCVkeHUh?=
EW-3	NHHqepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTNwOUi5NlMh\|ryP	M1TNT3NCVkeHUh?=
A704	NHvtfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr3TWM2OD12LkK4O\|I{KM7:TR?=	NGTVblRUSU6JRWK=
LU-139	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXKZ29ZUUN3ME20MlMyPTN2IN88US=>	NEjXeWdUSU6JRWK=
CAL-72	M{C3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;QXGlEPTB;ND60NVc1PiEQvF2=	M1LjNXNCVkeHUh?=
D-336MG	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETWdoNKSzVyPUSuOFY5OTdizszN	NIjoUmJUSU6JRWK=
LAMA-84	M3e1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS3TWM2OD12LkWzN\|Eh\|ryP	NWDwN\|k3W0GQR1XS
GI-ME-N	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHEXnc5UUN3ME20MlU1QDFizszN	M1;2dHNCVkeHUh?=
KM-H2	M3fHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjtb5hZUUN3ME20MlU2OjJ{IN88US=>	MXXTRW5ITVJ?
NCI-H209	M2nac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGL2SWhKSzVyPUSuOVgzQDNizszN	M3GxenNCVkeHUh?=
IGROV-1	M2jQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfKe\|JKSzVyPUSuPFcyPjhizszN	Mke5V2FPT0WU
L-363	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\HU2lEPTB;ND65OlY3PSEQvF2=	MV\TRW5ITVJ?
SK-MEL-3	NI[xNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\INGlEPTB;NT6yOFA3KM7:TR?=	NH2wZ2pUSU6JRWK=
HuO9	NH\VeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzuTWM2OD13LkO4PFQ{KM7:TR?=	NV7ZNnhCW0GQR1XS
NOS-1	M2jOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESxUINKSzVyPUWuO\|I6OjdizszN	NIXxOIdUSU6JRWK=
NCI-H1770	NHrFZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXjTWM2OD13Lkm1NFMzKM7:TR?=	NVXR[2J7W0GQR1XS
SF126	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTZwMkG0NFYh\|ryP	MXzTRW5ITVJ?
ML-2	NXXuSVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTZwMkS5O\|ch\|ryP	Mn3SV2FPT0WU
CHP-134	NVrnd5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[yTWM2OD14LkK1NVgzKM7:TR?=	NYPqWIVUW0GQR1XS
NCI-H1355	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\rXlNUUUN3ME22MlQyPzN\|IN88US=>	MVvTRW5ITVJ?
TE-12	M1TGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO1SVFKSzVyPU[uO\|I3PzFizszN	M17seHNCVkeHUh?=
A4-Fuk	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLTTWM2OD14LkezNVQzKM7:TR?=	M1L4eHNCVkeHUh?=
MV-4-11	NVu3NFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWno[\|EyUUN3ME22Mlc3PjJ4IN88US=>	NVnhW4hPW0GQR1XS
SK-UT-1	NUDVfZdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrkT2I3UUN3ME22MlkyPzh2IN88US=>	NWmzU49KW0GQR1XS
J-RT3-T3-5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fVdWlEPTB;Nz6wO\|c3PCEQvF2=	MnHPV2FPT0WU
ME-180	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjwTWM2OD15LkGwOFA1KM7:TR?=	Ml7oV2FPT0WU
SK-MEL-28	M1;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7TTWM2OD15LkO3PFE6KM7:TR?=	M33hVHNCVkeHUh?=
HAL-01	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTdwNEizOFEh\|ryP	M4TPb3NCVkeHUh?=
ES8	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nQXGlEPTB;Nz62PVYzPiEQvF2=	NFzKTYxUSU6JRWK=
DB	NX;tZ2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTnbY5uUUN3ME24MlEyPTB2IN88US=>	MmOxV2FPT0WU
SK-NEP-1	M3vqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:3TJVKSzVyPUiuOFgyPDlizszN	MmHGV2FPT0WU
COR-L88	NUHEdFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37RdWlEPTB;OD61NFk5OSEQvF2=	MXPTRW5ITVJ?
LB1047-RCC	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRThwNUKyNVIh\|ryP	MX;TRW5ITVJ?
NCI-H520	NHzDeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrVWFBUUUN3ME24MlYzOTV5IN88US=>	MX\TRW5ITVJ?
SW954	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPmbXZIUUN3ME24MlY6Pzh4IN88US=>	NWPVeFlLW0GQR1XS
TE-6	NHLLR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fPW2lEPTB;OD63OVE1OyEQvF2=	M{LNUnNCVkeHUh?=
D-283MED	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\4[VVKSzVyPUmuNFY2OzRizszN	MWTTRW5ITVJ?
DBTRG-05MG	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n0OmlEPTB;OT6wPVYxPyEQvF2=	MYXTRW5ITVJ?
NCI-H446	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37HO2lEPTB;OT6yPVUzPiEQvF2=	MYfTRW5ITVJ?
HOS	NYKyXnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXBcYRKSzVyPUmuN\|UyOzRizszN	M2X4dXNCVkeHUh?=
ES4	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTlwNUC1PVUh\|ryP	MUPTRW5ITVJ?
EW-13	NFGze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzYTWM2OD17Lki5NFU2KM7:TR?=	NH\nZWhUSU6JRWK=
IST-MES1	NUnRNVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLoOIxKSzVyPUmuPVQ2OzRizszN	MoX5V2FPT0WU
CAS-1	M4jLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTlwOUe2OVkh\|ryP	M1jLOHNCVkeHUh?=
EM-2	M32zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vNR2lEPTB;MUCuNVM6OyEQvF2=	MlvvV2FPT0WU
SW948	M2TSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTFyLkG4PFIh\|ryP	Mmm5V2FPT0WU
OAW-42	NIizVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jzd2lEPTB;MUCuOVI3PyEQvF2=	M2XT[3NCVkeHUh?=
BE-13	M1TyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HjV2lEPTB;MUCuOlU4PiEQvF2=	M2HwW3NCVkeHUh?=
KU812	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LrNGlEPTB;MUCuO\|M6OSEQvF2=	NY\JRmQ1W0GQR1XS
SK-MEL-30	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXKUoRjUUN3ME2xNE45QTBzIN88US=>	M33se3NCVkeHUh?=
A2780	M4HIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fKO2lEPTB;MUGuNFMxQCEQvF2=	NVPYdXZEW0GQR1XS
TGBC24TKB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLZNo1KSzVyPUGxMlA4OzdizszN	MmH3V2FPT0WU
GOTO	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;MTWM2OD1zMT6yNFg1KM7:TR?=	NXG5Z2hMW0GQR1XS
NCI-H526	NEfDOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\peWlEPTB;MUGuN\|g{PyEQvF2=	MmnJV2FPT0WU
BHT-101	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjsTWM2OD1zMT60OFU3KM7:TR?=	M2DsUXNCVkeHUh?=
NCI-H1155	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTFzLkS5OFch\|ryP	Mni1V2FPT0WU
MCF7	NY\5UI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFzLk[xOlch\|ryP	NVnIO4FKW0GQR1XS
MKN45	NUDiZ5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnKT5hKSzVyPUGxMlc6QTNizszN	NUH4bmtsW0GQR1XS
MOLT-16	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTFzLkm2PVIh\|ryP	NGnJSIRUSU6JRWK=
YH-13	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvyTnZ1UUN3ME2xNk4xOzR4IN88US=>	M1\PZnNCVkeHUh?=
P12-ICHIKAWA	NUHPbZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTF{LkO4OFUh\|ryP	NYXDWVE5W0GQR1XS
GR-ST	NE\zTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DLXWlEPTB;MUKuOVI6PSEQvF2=	MYfTRW5ITVJ?
CAKI-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T6NmlEPTB;MUKuO\|kyKM7:TR?=	NF7oUJBUSU6JRWK=
LXF-289	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\6T2NSUUN3ME2xN{4xQDN3IN88US=>	NHu5UGdUSU6JRWK=
MHH-PREB-1	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn72TWM2OD1zMz6yO\|A1KM7:TR?=	MWXTRW5ITVJ?
EW-16	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInp[oFKSzVyPUGzMlMyQDdizszN	NV;VN3UzW0GQR1XS
NCI-H82	NWHvd5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF62d2NKSzVyPUGzMlQyQTVizszN	NX3ofHVGW0GQR1XS
MMAC-SF	NHPXZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vUXmlEPTB;MUOuOFU1PyEQvF2=	MXLTRW5ITVJ?
COLO-684	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ruU2lEPTB;MUOuOVMyQCEQvF2=	MX\TRW5ITVJ?
QIMR-WIL	NITNW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTQbYJKSzVyPUGzMlgyODlizszN	NXzROoFyW0GQR1XS
NB69	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor4TWM2OD1zMz65PFY5KM7:TR?=	NVXoXpRXW0GQR1XS
NCI-H2291	NFXJVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;2TWM2OD1zND60OFU{KM7:TR?=	NV;4e25mW0GQR1XS
MKN7	NHXEV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XMS2lEPTB;MUSuOlY4PiEQvF2=	MXvTRW5ITVJ?
HDLM-2	MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF3LkGyPFYh\|ryP	NFLKVHNUSU6JRWK=
A253	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon4TWM2OD1zNT6zPFY6KM7:TR?=	NFro[XpUSU6JRWK=
SK-LU-1	NYjWOHU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33QPGlEPTB;MUWuPVA6PCEQvF2=	Ml7qV2FPT0WU
MEG-01	M3;Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnudWVPUUN3ME2xOU46OTB5IN88US=>	M{DhW3NCVkeHUh?=
SK-N-DZ	M4LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3OxfGlEPTB;MUWuPVM4PiEQvF2=	MUDTRW5ITVJ?
H4	NX3zOGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF4LkC4PEDPxE1?	MVrTRW5ITVJ?
LU-65	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF4LkOzPFQh\|ryP	Mo\zV2FPT0WU
NCI-H1048	NHHmUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojmTWM2OD1zNj61NVY2KM7:TR?=	MVnTRW5ITVJ?
LCLC-97TM1	NFrxZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz2NXBKSzVyPUG2MlU5QDlizszN	NH24VVRUSU6JRWK=
CAL-120	NEfLRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTF4Lkm4O\|kh\|ryP	MVHTRW5ITVJ?
LU-134-A	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXoTWM2OD1zNz6zN\|kyKM7:TR?=	NVvIb3JwW0GQR1XS
SK-MEL-1	NVzzW2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LPNWlEPTB;MUeuO\|EzPyEQvF2=	MYLTRW5ITVJ?
NCI-H69	NF;kRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTF5LkmzNFch\|ryP	M4TrOXNCVkeHUh?=
MC116	NXXj[ZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF5Lkm3OUDPxE1?	NE\XWJdUSU6JRWK=
UMC-11	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fsTmlEPTB;MUiuNVc5QCEQvF2=	Ml3SV2FPT0WU
HCC1395	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT3N2hKSzVyPUG4MlQ{ODFizszN	MXjTRW5ITVJ?
no-10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK4dYFwUUN3ME2xPE43Ozh6IN88US=>	NInYXYxUSU6JRWK=
NY	NHjReolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmzZWVKSzVyPUG5MlA5ODlizszN	M4LrcHNCVkeHUh?=
OS-RC-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjVZZJKSzVyPUG5MlEzPTJizszN	MmfIV2FPT0WU
D-423MG	M4\FNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr0eIdKSzVyPUG5MlM6PTJizszN	NH3YTG9USU6JRWK=
LC-2-ad	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvHWIZKSzVyPUG5Mlc3OTJizszN	MWrTRW5ITVJ?
DU-4475	NIfm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi3OVR7UUN3ME2xPU45QDV{IN88US=>	NVq5WlNOW0GQR1XS
YKG-1	NWDKXJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fscWlEPTB;MUmuPVYzKM7:TR?=	M3LOW3NCVkeHUh?=
HCC1569	M4r2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJyLkK2NlQh\|ryP	MkHaV2FPT0WU
TYK-nu	NE[4TWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3qTWM2OD1{MD6yPFQ4KM7:TR?=	MV\TRW5ITVJ?
DEL	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXxTWM2OD1{MD65PFA5KM7:TR?=	MnzvV2FPT0WU
MHH-ES-1	NWfteHlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LWUGlEPTB;MkGuN\|U6PyEQvF2=	MlfTV2FPT0WU
KARPAS-299	NFvMdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnreG5PUUN3ME2yNU42OjlizszN	MnPoV2FPT0WU
CTV-1	NV3hZ\|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XW[WlEPTB;MkGuOlE4OiEQvF2=	NVv4clFlW0GQR1XS
NCI-H2452	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7zZnpKSzVyPUKyMlY3PzdizszN	MWHTRW5ITVJ?
D-566MG	NIHabnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTJ{Lke2NFEh\|ryP	NELVSG5USU6JRWK=
EFO-27	NVHqTHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELDRoFKSzVyPUKzMlA3PTFizszN	NUPJTnRVW0GQR1XS
NCI-H596	NIPlZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLvN3lKSzVyPUKzMlg2OjdizszN	NUHlSnNNW0GQR1XS
KS-1	M2HqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vGVWlEPTB;MkSuNlc2QSEQvF2=	MWTTRW5ITVJ?
8305C	M{XDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjuSmRKSzVyPUK0MlQxPDVizszN	MYLTRW5ITVJ?
A427	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvsdIpKSzVyPUK1MlA{OjNizszN	NYLhcIZMW0GQR1XS
COLO-800	M3XVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTJ3LkGwOlEh\|ryP	M3ezZnNCVkeHUh?=
SJRH30	NWj4PGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDESHZzUUN3ME2yOU4{QTB6IN88US=>	NFzX[WhUSU6JRWK=
MEL-HO	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mom5TWM2OD1{NT60N\|E6KM7:TR?=	NIDYboZUSU6JRWK=
FTC-133	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrGTpR{UUN3ME2yOU45OTh4IN88US=>	MonMV2FPT0WU
SF295	NVTR[5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmruTWM2OD1{Nj6yPVYh\|ryP	MX\TRW5ITVJ?
SW1710	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnW2TWM2OD1{Nj60NVI{KM7:TR?=	M3LrenNCVkeHUh?=
EFM-19	NGLhcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJ4LkixOFUh\|ryP	M1TDOXNCVkeHUh?=
NB10	M375dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfLc5RyUUN3ME2yPE4zOjl5IN88US=>	Mn3ZV2FPT0WU
TK10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfwdpNIUUN3ME2yPE4zOzl7IN88US=>	Mn3OV2FPT0WU
D-502MG	NFfV[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO2SW5KSzVyPUK4MlQh\|ryP	MXjTRW5ITVJ?
EW-18	NYPjdW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHLc4ZKSzVyPUK4MlQ{QDZizszN	NEXweHlUSU6JRWK=
VMRC-RCZ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXvTWM2OD1{OD65OFEh\|ryP	MX\TRW5ITVJ?
Ca9-22	M2nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjMWGx6UUN3ME2yPU41PTV5IN88US=>	M4f6eHNCVkeHUh?=
KYSE-70	NUDYfnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDjTWM2OD1{OT61O\|g3KM7:TR?=	NFm0TmVUSU6JRWK=
A101D	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2m5W2lEPTB;MkmuOlQ4OiEQvF2=	NFviclRUSU6JRWK=
WM-115	M3j2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzZXVFQUUN3ME2yPU44PjB5IN88US=>	NHfoWolUSU6JRWK=
HCC2157	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLuTWM2OD1{OT64PFA4KM7:TR?=	M4C4SHNCVkeHUh?=
TE-9	M1nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDWZ3pKSzVyPUK5Mlg5PjVizszN	M{e0V3NCVkeHUh?=
K-562	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;mR2lEPTB;M{CuNFk{OyEQvF2=	MnjHV2FPT0WU
SN12C	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq4R2tKUUN3ME2zNE4yPDJ4IN88US=>	MY\TRW5ITVJ?
ESS-1	NV3xXmxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDkTWM2OD1\|MD60O\|U6KM7:TR?=	M3ziTHNCVkeHUh?=
K5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmruTWM2OD1\|MD63OlQh\|ryP	NVrYWo5nW0GQR1XS
J82	M{\pTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTENnVoUUN3ME2zNU4xQDl5IN88US=>	NF[1fVJUSU6JRWK=
HOP-92	NH36SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTNzLkGxNVEh\|ryP	MX;TRW5ITVJ?
NCI-H2228	MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jD[GlEPTB;M{GuN\|I6PiEQvF2=	MVHTRW5ITVJ?
OCI-AML2	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFezSIhKSzVyPUOxMlM3OSEQvF2=	NFXod41USU6JRWK=
NCI-SNU-5	NH2zeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEOzdXFKSzVyPUOxMlgyOzdizszN	M{TSPXNCVkeHUh?=
A3-KAW	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXITWM2OD1\|MT65NlQ{KM7:TR?=	MYrTRW5ITVJ?
LCLC-103H	NYHzW4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHxTWM2OD1\|Mj6wNVcyKM7:TR?=	MkCxV2FPT0WU
KY821	NWjme2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnO2TWM2OD1\|Mj62PFg1KM7:TR?=	MlXTV2FPT0WU
JVM-2	NIXaU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfCR3lnUUN3ME2zNk46ODd7IN88US=>	NYPQNWlHW0GQR1XS
Mo-T	M2jXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXwXmRWUUN3ME2zN{4yODB3IN88US=>	NFnOZlZUSU6JRWK=
IA-LM	NH21TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rtd2lEPTB;M{OuNlc2KM7:TR?=	NUPSe\|ZPW0GQR1XS
C8166	NHrUSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzkRW5oUUN3ME2zN{4{OTl{IN88US=>	NH;jOYlUSU6JRWK=
TCCSUP	M{SxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT3Wpo6UUN3ME2zN{41OzB5IN88US=>	MWDTRW5ITVJ?
JEG-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrhUYdKSzVyPUOzMlQ4PjhizszN	M3fJSHNCVkeHUh?=
MS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ezb2lEPTB;M{OuOVU2OSEQvF2=	NEfXT\|dUSU6JRWK=
NCI-H1304	NEfwcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXNVVNsUUN3ME2zN{42PzJ3IN88US=>	MY\TRW5ITVJ?
Ramos-2G6-4C10	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTN2LkCzN\|Uh\|ryP	M4juSXNCVkeHUh?=
MDA-MB-453	M{LqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr2UmhRUUN3ME2zOE43Ozl3IN88US=>	M4fNVHNCVkeHUh?=
KYSE-520	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\3TWM2OD1\|ND63NVgyKM7:TR?=	NUn4bJdMW0GQR1XS
SW900	NXzn[HRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXThXm9OUUN3ME2zOE45OTF3IN88US=>	M1;RXHNCVkeHUh?=
HCC2998	NFzxSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7OTWM2OD1\|NT6xOVI6KM7:TR?=	MXjTRW5ITVJ?
A2058	NXHOcpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fZSGlEPTB;M{WuOlA3OSEQvF2=	MYrTRW5ITVJ?
OVCAR-3	NH7YPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTN4LkKwOFUh\|ryP	M3e5c3NCVkeHUh?=
MOLT-4	NWrh[HFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrBXnFKSzVyPUO2MlIzQTRizszN	NVLVO\|AxW0GQR1XS
CAPAN-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLuTWM2OD1\|Nj60Olk6KM7:TR?=	NXrMepJPW0GQR1XS
SCC-9	NH:4WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TGUWlEPTB;M{euOFAzPyEQvF2=	MkDCV2FPT0WU
SF268	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFm1Nm5KSzVyPUO4MlM1OzNizszN	NU\IbnRPW0GQR1XS
HGC-27	NV\R[XE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXkboI6UUN3ME2zPE4{PzFzIN88US=>	MmnkV2FPT0WU
DOHH-2	M3XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1THN2lEPTB;M{iuO\|E2QCEQvF2=	M1PlSnNCVkeHUh?=
KE-37	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPJW4FHUUN3ME2zPE46QDJ6IN88US=>	NVTKfJlmW0GQR1XS
MOLT-13	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Xa[WlEPTB;M{muNlUxOiEQvF2=	NH[4OZZUSU6JRWK=
ES1	NV7BfGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTN7LkO4OUDPxE1?	M3;tN3NCVkeHUh?=
SK-OV-3	NE\4N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTN7Lkm2OFMh\|ryP	NFq2dXJUSU6JRWK=
SNU-449	NVTMcYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTRyLkC3OlQh\|ryP	NVLMPHQ4W0GQR1XS
KYSE-510	NXW3O2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPsTWM2OD12MD6xNlk2KM7:TR?=	M{\4ZXNCVkeHUh?=
HL-60	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf3eWRKSzVyPUSwMlk4QDNizszN	NV7NT3c{W0GQR1XS
DJM-1	NXG2OlRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoK0TWM2OD12MD65O\|k6KM7:TR?=	NUX4RpE6W0GQR1XS
TGBC11TKB	NWP0c3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTRzLkC5NlYh\|ryP	MV3TRW5ITVJ?
U-2-OS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn0SGF4UUN3ME20Nk4zPjRzIN88US=>	NXi2Rmg{W0GQR1XS
NCI-H2030	NH;4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHT3UHNKSzVyPUSyMlQ{PjhizszN	NV\NeWJrW0GQR1XS
LU-135	NUPYSmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XvZmlEPTB;NEKuOVQ1PyEQvF2=	MWXTRW5ITVJ?
ZR-75-30	NHnCNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[wTWM2OD12Mz6wOFk{KM7:TR?=	M4PRfHNCVkeHUh?=
GT3TKB	NXHTWZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTR\|LkK2O\|kh\|ryP	NGfiSY5USU6JRWK=
RPMI-2650	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLCTWM2OD12Mz63PFE3KM7:TR?=	MXnTRW5ITVJ?
SAS	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTR\|Lkm1N\|Qh\|ryP	MVHTRW5ITVJ?
MDA-MB-231	NHeyVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;qT3NKSzVyPUSzMlk3ODlizszN	MmHtV2FPT0WU
JVM-3	NF63bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTR2LkC1N\|Mh\|ryP	NXTDPZhuW0GQR1XS
COLO-320-HSR	NHjDWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDrc5F2UUN3ME20OE42PjN\|IN88US=>	MnfGV2FPT0WU
SNB75	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTR2Lk[xNFUh\|ryP	MnfsV2FPT0WU
NCI-H441	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rEVWlEPTB;NESuPVMzQCEQvF2=	MkjrV2FPT0WU
HCT-116	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDjTWM2OD12ND65PFY5KM7:TR?=	MofvV2FPT0WU
NCI-H226	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[0bGdKSzVyPUS1MlY{PjhizszN	MXvTRW5ITVJ?
CAL-33	NILafmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknrTWM2OD12NT65NlE4KM7:TR?=	NITC[mdUSU6JRWK=
NCI-H1437	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoflTWM2OD12Nj6zNlEh\|ryP	M4TqXnNCVkeHUh?=
HCC1187	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXJbVZ2UUN3ME20Ok41OjV3IN88US=>	MYHTRW5ITVJ?
NUGC-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37s[GlEPTB;NE[uOVcxQSEQvF2=	NYDUXZNyW0GQR1XS
T98G	M1jx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\DU4dKSzVyPUS3MlU1PyEQvF2=	NX;XZYtJW0GQR1XS
OVCAR-8	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLzTWM2OD12Nz62PFMh\|ryP	Mlr3V2FPT0WU
LB2241-RCC	M1TPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jrN2lEPTB;NEeuO\|I4KM7:TR?=	NEixdYFUSU6JRWK=
NCI-H358	NFXxfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLRRVdQUUN3ME20PE4yOTV{IN88US=>	NF\XU2tUSU6JRWK=
PANC-08-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rLNmlEPTB;NEiuNVg2OyEQvF2=	MY\TRW5ITVJ?
KP-N-YN	NGLlWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHGTWM2OD12OD6yNVAzKM7:TR?=	MV3TRW5ITVJ?
NCI-H1755	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XtS2lEPTB;NEiuNlczPiEQvF2=	NELFS3dUSU6JRWK=
NCI-N87	M2HPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf2cG9KSzVyPUS4MlI6QTFizszN	NF:zRm9USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

In vivo

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-³²P]ATP (5 μM ATP containing 0.4 μCi of [γ-³²P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [³²P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:^[4]	- Collapse Cell lines: KMS11 and KMS18 Concentrations: Dissolved in DMSO, final concentrations ~100 nM Incubation Time: 48 hours Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Swiss Webster mice with induced corneal angiogenesis Dosages: ~2 mg/kg/day Administration: Administered intraperitoneally (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD173074 SDF

Molecular Weight	523.67
Formula	C₂₈H₄₁N₇O₃
CAS No.	219580-11-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of PD173074(S1264) in vivo?
Answer:
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Pan FGFR Inhibitor

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
Most Potent FGFR Inhibitor

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Related FGFR Products

CH5183284 (Debio-1347) ^New

CH5183284 (Debio-1347, FF284) is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Infigratinib (BGJ398)

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
AZD4547

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074